6
Registered trials
2
Recruiting
6
Unique sponsors
5
Unique IMPs
4
Commercial trials
Drug classes (ATC)
—
ATC code not specified
5
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Kinase inhibitor
1 substance
Checkpoint inhibitor (PD-L1)
1 substance
Monoclonal antibody
1 substance
Phase II:
3
Phase I:
2
Phase I (Other):
1
Phase II
3 trials-
RecruitingBayer Consumer Care AG Commercial3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
-
EndedCentre Leon Berard AcademicATEZOLIZUMAB
-
RecruitingUnicancer AcademicZANIDATAMAB
Phase I
2 trials-
EndedCebiotex S.L. CommercialIMP not specified
-
EndedValo Therapeutics Oy CommercialIMP not specified
Phase I (Other)
1 trial-
EndedExelixis Inc. CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Cebiotex S.L. | Commercial | 1 | Phase I | 0 |
| Valo Therapeutics Oy | Commercial | 1 | Phase I | 0 |
| Exelixis Inc. | Commercial | 1 | Phase I (Other) | 0 |
| Bayer Consumer Care AG | Commercial | 1 | Phase II | 1 |
| Centre Leon Berard | Academic | 1 | Phase II | 0 |
| Unicancer | Academic | 1 | Phase II | 1 |
New trials by year
2023
2
2024
1
2025
2